<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917018</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmed EA</org_study_id>
    <nct_id>NCT02917018</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Stress Response and Emergence Agitation During Laparoscopic Surgery</brief_title>
  <official_title>Effect of Different Doses of Dexmedetomidine on Stress Response and Emergence Agitation After Laparoscopic Cholecystectomy in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emergence agitation is a post-anesthetic phenomenon that develops in the early phase of&#xD;
      general anesthesia recovery, and is characterized by agitation, confusion, disorientation,&#xD;
      and possible violent behavior. The incidence of emergence agitation is less common in adults&#xD;
      as compared to pediatric patients. It may lead to serious consequences for the patient such&#xD;
      as bleeding, falling, removal of catheters and self extubation, which lead to further&#xD;
      complications like hypoxia and aspiration.&#xD;
&#xD;
      Despite its common occurrence, unclear etiology, and serious sequelae, emergence agitation&#xD;
      has rarely been studied in adults.&#xD;
&#xD;
      The stress response to surgery is an unconscious response to tissue injury. Activation of the&#xD;
      sympathetic nervous system, increase of catabolic hormone release and pituitary gland&#xD;
      suppression are considered a response to surgical stress, in clinical practice these&#xD;
      activities cause changes in heart rate, blood pressure and biochemical fluctuations of&#xD;
      noradrenaline, adrenaline, dopamine, and cortisol. Above all, these fluctuations prolong&#xD;
      hospitalization and delay patients discharge.&#xD;
&#xD;
      Dexmedetomidine is a highly selective alpha-2 receptor agonist having sedative, analgesic and&#xD;
      sympatholytic properties. Decreased stress response to surgery ensuring a stable hemodynamic&#xD;
      state is a beneficial property of the agent. Peri-operative use of dexmedetomidine also&#xD;
      decreases postoperative opioid consumption, pain intensity, and antiemetic therapy. However,&#xD;
      the data related to the effects of dexmedetomidine on reducing agitation from general&#xD;
      anesthesia in adults are limited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With no premedication, all patients will have pre-oxygenation for 3-5 minutes and intravenous&#xD;
      access will be secured. NaCl 0.9% 4 ml/kg/h will be infused intraoperatively. General&#xD;
      anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg and nimbex (cisatracurium)&#xD;
      0.15 mg/kg. Endotracheal intubation then will be done using oral ETT of appropriate size&#xD;
      under direct laryngoscopy and secured at the angle of the mouth. Sevoflurane inhalational&#xD;
      anesthetic (2-4 %) and nimbex 0.03 mg/kg will be used for maintenance of anesthesia. The&#xD;
      lungs will be mechanically ventilated to keep intra-operative EtCo2 between 35-40 mmHg.&#xD;
&#xD;
      Intraoperative monitoring:&#xD;
&#xD;
      Routine monitors including ECG, non-invasive blood pressure, pulse oxymetry and EtCo2 will be&#xD;
      recorded every 5 minutes during the intra-operative 20 minutes of the study drug&#xD;
      administration. Bradycadia (heart rate ˂ 60 beat/minute) will be treated with iv atropine 0.5&#xD;
      mg. Hypotension (mean arterial blood pressure ˂ 60 mmHg) will be treated with iv ephedrine 5&#xD;
      mg increments. Duration of anesthesia, sevoflurane % and duration of surgery will be&#xD;
      recorded.&#xD;
&#xD;
      At the end of surgery and stoppage of sevoflurane inhalation, neostigmine 0.04 mg/kg and&#xD;
      atropine 0.02 mg/kg will be used for muscle relaxant reversal (Time 0 in the emergence&#xD;
      process), patients will be extubated and transferred to the PACU for recovery and monitoring.&#xD;
&#xD;
      Assessment in PACU:&#xD;
&#xD;
      Routine monitoring will be continued during staying in PACU. During emergence, the level of&#xD;
      agitation will be evaluated using the Ricker sedation-agitation scale (RSAS). The maximum&#xD;
      level of agitation will be recorded for each patient at time 0, 5, 10, 20, 30, 60 and 120&#xD;
      minutes. Emergence agitation was defined as any score on the sedation-agitation scale ≥ 5.&#xD;
      Dangerous agitation was defined as a sedation-agitation scale score = 7 (3). If dangerous&#xD;
      agitation occurs, it will be treated with fentanyl 1 ug/kg.&#xD;
&#xD;
      Duration of stay in PACU will be recorded. Criteria for discharge from PACU will be applied&#xD;
      according to the modified Aldrete scoring system. A score ≥ 9 was required for discharge.&#xD;
&#xD;
      Postoperative Analgesia:&#xD;
&#xD;
      The 10 points Visual Analogue Scale (VAS) for pain measurement will be used to assess the&#xD;
      severity of postoperative pain. Score 0 indicates no pain and score 10 indicates severe pain.&#xD;
      If VAS ≥ 4, rescue analgesia will be indicated. Perfalgan infusion will be used as&#xD;
      supplemental analgesia. The first dose and the total amount in 24 hours of perfalgan will be&#xD;
      recorded. Patient's satisfaction will be recorded at the end of the first 24 hours&#xD;
      postoperatively.&#xD;
&#xD;
      Blood Sampling:&#xD;
&#xD;
      Venous blood samples will be collected from peripheral extremities away from the intravenous&#xD;
      infused limb. Samples will be withdrawn 30 minutes pre-operatively, 30 minutes after skin&#xD;
      incision, 2 and 24 hours after end of surgery. The blood samples will be centrifuged at 3500&#xD;
      ×g for at least 10 minutes and then serum samples will be eluted. Blood glucose level will be&#xD;
      also recorded at the same times.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      Statistical analysis will be conducted with SPSS version 20 (SPSS Inc., Chicago, IL, USA) for&#xD;
      Windows. The results will be expressed as mean ± SD, range, percentage. P-values &lt; 0.05 will&#xD;
      be considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum cortisol level</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>serum cortisol level will be measured at 2 hours postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post anesthetic emergence agitation</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>RSAS score will be measured 2 hours postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue score</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>perfalgan will be given when visual analogue score ≥ 4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Stress Response</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive dexmedetomidine 1 mic/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.75</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive dexmedetomidine 0.75 mic/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive dexmedetomidine 0.5 mic/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.</description>
    <arm_group_label>Dexmedetomidine 0.5</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.75</arm_group_label>
    <arm_group_label>Dexmedetomidine 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I - II Laparoscopic cholecystectomy under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac disease, diabetes. reactive upper airway disease. allergies to&#xD;
             dexmedetomidine. cognitive disorders. renal insufficiency. hepatic dysfunction.&#xD;
             Chronic use of analgesics, cortisone or drugs known to interact with dexmedetomidine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamdy Yossef, MD</last_name>
    <role>Study Chair</role>
    <affiliation>assiut university, faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MOHAMED F. MOSTAFA</investigator_full_name>
    <investigator_title>lecturer of anesthesia and intensive care, faculty of medicine, Assiut university</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Stress response</keyword>
  <keyword>Emergence agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

